Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

Jessica Spahn; Jing Peng; Edward Lorenzana; David Kan; Thomas Hunsaker; Ehud Segal; Mario Mautino; Erik Brincks; Andrea Pirzkall; Sean Kelley; Sami Mahrus; Liling Liu; Stephanie Dale; Cristine Quiason; Elizabeth Jones; Yichin Liu; Sheerin Latham; Laurent Salphati; Kevin DeMent; Mark Merchant; Georgia Hatzivassiliou

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

【24h】

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

机译：在临床前肿瘤模型中，将IDO1抑制剂GDC-0919与抗PD-1l阻断剂联合使用相比，单独使用抗PD-1l阻断剂具有更高的抗肿瘤免疫力和功效

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer》 |2015年第s2期|共页
作者
Jessica Spahn; Jing Peng; Edward Lorenzana; David Kan; Thomas Hunsaker; Ehud Segal; Mario Mautino; Erik Brincks; Andrea Pirzkall; Sean Kelley; Sami Mahrus; Liling Liu; Stephanie Dale; Cristine Quiason; Elizabeth Jones; Yichin Liu; Sheerin Latham; Laurent Salphati; Kevin DeMent; Mark Merchant; Georgia Hatzivassiliou;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model [J] . Mony Jyothi Thyagabhavan, Zhang Lixin, Ma Tianzhou, Cancer immunology, immunotherapy : . 2015,第9期

机译：在人类MUC1表达的临床前卵巢癌模型中，抗PD-L1可以延长生存期并触发T细胞，但不会触发体液抗肿瘤免疫反应
2. 151 Allosteric {MEK} inhibitor {BAY} 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer [J] . F. Puehler, A. Scholz, M. Kissel, European Journal of Cancer Supplements . 2010,第7期

机译：151变构 {MEK }抑制剂 {BAY } 86-9766（RDEA119）在肝细胞癌和胰腺癌的临床前模型中显示单一疗法和联合疗法的抗肿瘤功效
3. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy [J] . Anne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, Journal for ImmunoTherapy of Cancer . 2020,第2期

机译：CDK4 / 6抑制抑制在临床前模型中提高化疗和免疫检查点抑制剂组合的抗肿瘤功效，增强了SCLC接受化疗的患者T细胞活化
4. Combination of angiogenesis inhibitors increases the anti-tumor efficacy of photodynamic therapy in a human bladder tumor xenograft model [C] . Ramaswamy Bhuvaneswari, Yik Yuen Gan, Patricia SP Thong, World congress of the International Photodynamic Association . 2009

机译：血管生成抑制剂的组合增加了光动力疗法在人膀胱肿瘤异种移植模型中的抗肿瘤功效
5. Understanding How Adrenergic Stress Signaling Impacts the Anti-Tumor Immune Response and the Efficacy of Checkpoint Inhibitors in Murine Tumor Models [D] . Bucsek, Mark Joseph. 2019

机译：了解肾上腺素能应激信号如何影响抗肿瘤免疫应答以及检查点抑制剂在鼠肿瘤模型中的疗效
6. Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models [O] . Jessica Spahn, Jing Peng, Edward Lorenzana, 2015

机译：在临床前肿瘤模型中将IDO1抑制剂GDC-0919与抗PD-1l阻断剂联合使用相比单独使用抗PD-1l阻断剂具有更高的抗肿瘤免疫力和功效
7. Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models [O] . 2015

机译：在临床前肿瘤模型中，将IDO1抑制剂GDC-0919与抗PD-1l阻断剂联合使用相比，单独使用抗PD-1l阻断剂具有更高的抗肿瘤免疫力和功效

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

著录项

相似文献

相关主题

期刊订阅